id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-331243-0u65qguq	Ucciferri, Claudio	Role of monoclonal antibody drugs in the treatment of COVID-19	2020-10-06		.txt	text/plain	1695	94	39	Evidence suggests that elevated cytokine levels, reflecting a hyperinflammatory response secondary to SARS-CoV-2 infection, are responsible for multi-organ damage in patients with COVID-19. These studies suggest that tocilizumab may be a candidate to improve the outcome of patients with severe COVID-19 infections. Recent data on anakinra showed that, in a cohort of patients with COVID-19 and Acute respiratory distress syndrome managed with non-invasive mechanical ventilation, treatment with highdose anakinra was safe and associated with clinical improvement [16, 17] . Currently available data on SARS-CoV-2 infection show that the extent of the inflammatory response correlates with disease progression and subsequent organ damage. Tocilizumab for the treatment of severe COVID-19 pneumonia with hyperinflammatory syndrome and acute respiratory failure: A single center study of 100 patients in Interleukin-1 blockade with high-dose anakinra in patients with COVID-19, acute respiratory distress syndrome, and hyperinflammation: a retrospective cohort study	./cache/cord-331243-0u65qguq.txt	./txt/cord-331243-0u65qguq.txt